Other News

WELL Health Launches its AI-POWERED Co-pilot for Cardiologists powered by HEALWELL AI to Help Improve Detection of Cardiovascular Disease

Coronary/Structural Heart by Comments are Disabled

WELL has launched its new AI-powered physician co-pilot to assist cardiologists in better identifying patients at high risk of cardiovascular disease (“CVD”). WELL is exclusively partnering with HEALWELL AI, a leader in AI enabled disease diagnosis, as an extension of the WELL AI Decision Support (“WAIDS”) product offering.
The co-pilot will be deployed into WELL Diagnostic Centres, Canada’s largest cardiology and medical diagnostic group, providing support and assisting cardiologists in over 40 locations across Ontario.
CVD stands as the leading cause of death globally, accounting for approximately 32% of deaths worldwide in 2019(1), underscoring the critical need for early detection. HEALWELL also expects to leverage this technology to help accelerate life sciences research and development opportunities related to CVD and drive new business opportunities for its newly acquired Clinical Research Organization (“CRO”), BioPharma Services Inc.

VANCOUVER, BC and TORONTO, July 17, 2024 /PRNewswire/ – WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (“WELL” or the “Company”) a digital health company focused on tech-enabling healthcare providers, and its investee company, HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) (“HEALWELL”), a healthcare technology company focused on AI and data science for preventative care, are jointly pleased to announce the launch of WELL’s AI-powered co-pilot for cardiologists exclusively powered by HEALWELL AI, aimed at identifying patients at high risk of cardiovascular disease (“CVD”). This significant expansion of WELL’s AI capabilities builds on the success of its second-generation AI-powered physician co-pilot, WELL AI Decision Support (“WAIDS”), developed exclusively in partnership with HEALWELL. This enhancement adds to its existing rare and chronic disease detection abilities and is an extension to the WAIDS offering.
The co-pilot for cardiologists will be deployed in WELL Diagnostics Centres, Canada’s largest cardiology and medical diagnostic group with over 40 locations in Ontario. It will be available to cardiologists within the WELL Diagnostic Centres ecosystem, providing invaluable support in the early detection and management of cardiovascular disease.
Dina Sergi, CEO of WELL Diagnostic Centres, highlighted the tool’s impact, “The integration of HEALWELL’s AI-powered co-pilot for cardiologists into our WELL Diagnostic Centres represents a game-changing advancement. By offering precise risk stratification and actionable insights, this tool enhances their ability to proactively manage cardiovascular health and improve patient care.”
Dr. Alexander Dobranowski, CEO of HEALWELL, commented, “The launch of our AI-powered co-pilot for specialists marks a significant milestone in our mission to enhance healthcare through advanced technology. By expanding our AI capabilities to include cardiovascular disease detection, we are equipping cardiologists with enhanced tools and decision support necessary to identify at-risk patients earlier, ultimately improving patient outcomes and reducing healthcare costs. The integration of this tool into WELL’s Diagnostic Centres is particularly important, as it provides us access to Canada’s largest cardiology group. This vast dataset not only assists hundreds of cardiologists within the WELL Diagnostic Centres ecosystem but also allows us to continuously refine and enhance the co-pilot.”
Dr. Paul Kannampuzha, Chief Cardiology Officer of WELL Diagnostic Centres commented. “As a cardiologist, I am encouraged by how AI can help provide improved disease detection and decision support for cardiologists across the country. I believe this technology will help drive improved preventative care and ensure patients don’t fall through the cracks.”
Cardiovascular disease (CVD) is a group of disorders affecting the heart and blood vessels and is the leading cause of death globally, responsible for approximately 32% of deaths worldwide in 2019(1). In Canada, recent estimates suggest that CVD costs about $22 billion per year and is considered the second leading contributor to healthcare costs(2). Identifying patients with worsening cardiovascular conditions earlier is crucial, as cardiovascular disease is the third leading cause of death in Canada.
The global market for pharmaceutical drugs supporting cardiovascular disease was valued at approximately USD 144.1 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of approximately 4% over the next decade, reaching an estimated USD 207.8 billion by 2033 (Precedence Research)(3). HEALWELL expects to leverage this technology to help accelerate life sciences research and development opportunities related to CVD and drive new business opportunities for its newly acquired Clinical Research Organization (CRO), BioPharma Services Inc.
Footnotes:

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29
https://link.springer.com/article/10.1007/s41669-021-00257-8
https://www.precedenceresearch.com/cardiovascular-drugs-market

About WELL Health Technologies Corp.
WELL’s mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL’s comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL’s solutions enable more than 34,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 175 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL’s solutions are focused on specialized markets such as the gastrointestinal market, women’s health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol “WELL” and on the OTC Exchange under the symbol “WHTCF”. To learn more about WELL, please visit: www.well.company.
About HEALWELL AI
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary AI technology and competencies which includes data science, electronic health records and clinical research offerings, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/.
Forward-Looking Statements
Certain statements in this press release, constitute “forward-looking information” and “forward looking statements” (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to, among other things, the deployment of WAIDS at WELL Health Diagnostic Centres, the use of the WAIDS to improve patient care, and the use of AI technology by HEALWELL to drive research and development opportunities related to CVD. Forward-looking statements are often, but not always, identified by words or phrases such as “opportunity”, “potential”, “improve”, “expect”, “intend”, “create” or variations of such words and phrases or statements that certain future conditions, actions, events or results “will”, “may”, “could”, “would”, “should”, “might” or “can” be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL’s control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to: the ability of HEALWELL to utilize AI technologies to detect CVD indicators; the ability to collaborate with the pharmaceutical industry for research and development opportunities, HEALWELL’s continued compliance with third party intellectual property rights; HEALWELL’s continued compliance with privacy laws; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL’s business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled “Risk Factors” in HEALWELL’s most recent annual information form dated April 1, 2024, which is available under HEALWELL’s SEDAR+ profile at www.sedarplus.com. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
SOURCE WELL Health Technologies Corp.

Continue Reading →

LeMaitre Will Announce Second Quarter 2024 Earnings Results August 1, 2024

Financial by Comments are Disabled

BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com. LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.

Continue Reading →

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

Financial by 0 comments

July 16, 2024 06:30 AM Eastern Daylight Time LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth […]

Continue Reading →

Inari Medical to Announce Second Quarter 2024 Financial Results

Financial by Comments are Disabled

IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website or by registering here. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website. About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram. Investor Contact: Marissa BychGilmartin Group LLCIR@inarimedical.com

Continue Reading →

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases

Financial by 0 comments

July 16, 2024 09:00 AM Eastern Daylight Time BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has raised a $260 million Series B financing led by Ascenta Capital, with participation by new investors NEA, GV, Fidelity Management […]

Continue Reading →

Faraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI

Coronary/Structural Heart by Comments are Disabled

SEATTLE, July 16, 2024 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced it will host a virtual KOL webinar on Tuesday, July 30, 2024, at 11:00 AM ET. To register for the webinar, click here. The webinar will feature Dr. Cheerag Shirodaria (Oxford University Hospitals), Dr. Marc Bonaca (University of Colorado Anschutz), and Dr. Antonio Gutierrez (Duke University Hospital and Durham VA Medical Center), who will discuss the unmet need and current treatment landscape in preventing ischemia-reperfusion injury and highlight the effects of STEMI on heart failure and other patient outcomes. The webinar will also review data from the development of FDY-5301, an investigational product being evaluated by Faraday in minimizing cardiac damage following acute STEMI. The company’s pivotal Phase 3 Iocyte AMI-3 trial of FDY-5301 in anterior STEMI patients undergoing primary percutaneous intervention is now fully enrolled with topline data anticipated in 2H 2025. A live question and answer session will follow the formal presentations. About Cheerag Shirodaria, BSc, MBBS, MD, FRCP, MBA Dr. Cheerag Shirodaria is Chief Development Officer at Caristo Diagnostics and a Cardiologist at Oxford University Hospitals in the UK. He is an interventional cardiologist who is also an expert in cardiac imaging, particularly cardiac MRI (CMR) and coronary CT angiography (CCTA), having completed his doctoral thesis in Oxford on novel vascular imaging techniques using CMR. He was heavily involved in the design and execution of the phase 2 STEMI trial involving FDY-5301 and is a member of the Executive Steering Committee of the IOCYTE-AMI trial. As co-founder and former CEO of Caristo, he has developed and commercialized novel imaging AI imaging tools to predict future cardiometabolic risk. Dr Shirodaria obtained his medical degree from St Bartholomew’s Hospital Medical College, his medical doctorate from the University of Oxford and his MBA from London Business School. About Marc Bonaca, MD, MPH Dr. Marc Bonaca is a cardiologist and vascular medicine specialist serving as executive director of CPC and Director of Vascular Research & Professor of Medicine at the University of Colorado Anschutz. Dr. Bonaca earned his medical degree from the University of Connecticut and his MPH at Harvard. He completed his medical residency, cardiology fellowship, and vascular medicine fellowship at Brigham and Women’s Hospital and a dedicated research fellowship at the TIMI Study Group. He became faculty at BWH and Harvard Medical School and an investigator at TIMI. He directed pharmacovigilance at TIMI and was an investigator on several large outcomes trials including TRA2P-TIMI 50, PEGASUS-TIMI 54, DECLARE-TIMI 58, and REAL TIMI 63B. In 2018, he joined the faculty at the University of Colorado as Professor of Medicine and the William R. Hiatt Endowed Chair in Cardiovascular Research. He is the Executive Director of CPC, an affiliated non-profit Academic Research Organization. At CPC, he has led several clinical trials with CPC as the lead ARO, including VOYAGER PAD, PREVENT HD, and ASPEN, and is leading several ongoing trials, including BRIGHT and EVOLVE MI, a 4000-patient pragmatic multinational acute coronary syndrome trial. Dr. Bonaca’s research focus is on ischemic risk with atherosclerotic vascular disease, risk prediction, and risk modification using pharmacologic and biologic therapies. He has extensive experience designing and conducting large, multicenter randomized clinical trials, and analyzing registries and real-world datasets. His areas of interest include PAD, PVD, and diabetes, with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications, and major adverse cardiovascular events. He is also investigating the cardiac, vascular, and thrombotic complications associated with novel oncologic therapies. At CPC, he has focused on building a robust faculty and operational group dedicated to high quality, efficient trials leveraging health networks, informatics, and decentralized design. About J. Antonio T. Gutierrez, MD Dr. Antonio Gutierrez’s clinical interests include diagnostic and interventional coronary angiography, peripheral angiography and percutaneous intervention, and vascular medicine. His research interests are focused on peripheral artery disease. He has been involved in multiple clinical trials involving patients with atherosclerotic disease and has published several peer-reviewed articles and reviews. Dr. Gutierrez received his Bachelor of Arts from the College of the Holy Cross in 2000, Doctorate of Medicine from Case Western Reserve University School of Medicine in 2007, and Masters of Health Science in Clinical Research from Duke University School of Medicine in 2012. He completed his residency in Internal Medicine at Duke University Medical Center in 2010 and was appointed Chief Medical Resident of the Durham VA Medical Center in 2011. Dr. Gutierrez completed his General Cardiology and Vascular Medicine Fellowships at Brigham and Women’s Hospital and a Clinical Research Fellowship at the TIMI Study Group. Most recently Dr. Gutierrez matriculated his Interventional Cardiology Fellowship at Duke University Medical Center. Dr. Gutierrez is currently an Assistant Professor of Medicine at Duke University Hospital and Staff Physician at the Durham VA Medical Center. About STEMI Acute STEMI is a leading cause of cardiovascular death and remains a primary cause of the development of heart failure. Standard treatment of a STEMI involves PCI, during which a catheter is inserted into the artery to remove the blockage and restore blood flow. Following a STEMI, one of the critical factors influencing patient outcomes is reperfusion injury, which occurs when the oxygen-rich blood supply returns to the ischemic heart muscle. About FDY-5301 FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Faraday has selected FDY-5301 for investigation in the belief that its properties are well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. A Phase 2 clinical trial of FDY-5301 in STEMI patients demonstrated that it was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage. Results from that trial — known as Iocyte AMI — were reported in the January 15, 2022, issue of the International Journal of Cardiology. About Faraday Pharmaceuticals, Inc. Faraday Pharmaceuticals® is a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute STEMI. The company was founded by Dr. Mark Roth of the Fred Hutch Cancer Center and is backed by an investor group led by ARCH Venture Partners and Polaris Partners. The company’s lead program, FDY-5301, is in a pivotal Phase 3 trial and is designed to reduce IRI in acute STEMI, a leading cause of death and a primary cause of the development of heart failure. The company is headquartered in Seattle. For more information, visit www.faradaypharma.com or follow the company on LinkedIn. Contact:Brian BlackmanChief Financial Officerbblackman@faradaypharma.com Contact:PJ KelleherLifeSci Advisors, LLC+1-617-430-7579pkelleher@lifesciadvisors.com

Continue Reading →

SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography

Coronary/Structural Heart by Comments are Disabled

MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) — HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on the use of coronary computed tomography angiography (coronary CTA) in coronary artery disease (CAD) management and insights on CTA reimbursement at the upcoming 19th Annual Scientific Meeting of SCCT. The annual meeting will take place on July 18-21, 2024 in Washington, D.C. Subset data from the PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) Trial will also be presented. The PRECISE clinical trial data, originally presented in late 2022, confirmed CTA + FFRCT increases diagnostic accuracy, reduces unnecessary testing and offers higher confidence in identifying patients needing treatment versus traditional testing (stress nuclear, stress echo, and invasive coronary angiography). The new subset data analyzes the association between body mass index, testing performance and clinical outcomes in patients with stable chest pain. New insights from the ADVANCE Registry, including analysis on the relationship between risk factors and quantified atherosclerotic burden and differences in plaque quantification in a Japanese patient population will be shared. Along with the significant work HeartFlow has undertaken to develop age and sex specific nomograms, these data will be a pivotal step to better stratify patients and impact treatment decisions going forward. “The critical role of CTA in the diagnosis and management of coronary artery disease continues to drive every decision we make, ensuring the right patients are getting the right care at the right time,” said Campbell Rogers, Chief Medical Officer of HeartFlow. “This year, we are excited to share the latest insights on the importance of quantifying coronary artery plaque, as well as changes in the reimbursement landscape. We are pleased to continue providing robust clinical evidence as to how our products can help health care providers manage their patient’s heart health.” Details of the presentations are as follows: Session: Poster Session 8 – CT in Non-Acute Chest PainTitle: “Association Between Body Mass Index, Testing Performance And Clinical Outcomes In Patients With Stable Chest Pain: Insights From The PRECISE Trial”Date: Friday, July 19, 2024Time: 9:30 – 10:15 AM EDTLocation: Exhibit Hall Session: Poster Session 16 – Plaque ImagingTitle: The Relationship Of Risk Factors And Quantified Atherosclerotic Burden On Coronary Computed Tomographic Angiography – Lessons From The ADVANCE RegistryDate: Saturday, July 20 Time: 9:30 – 10:35 AM EDTLocation: Exhibit Hall Session: Poster Session 16 – Plaque ImagingTitle: Quantitative Differences Between Japanese And Non-Japanese Patients’ Coronary Computed Tomographic Angiography Derived Plaque – Insights From The ADVANCE RegistryDate: Saturday, July 20 Time: 9:30 – 10:35 AM EDTLocation: Exhibit Hall Session: Business Aspects of Cardiac CT – Part TwoTitle: “How clinicians can work with administrators to maximize cardiac CT reimbursement” Presenter: Cara SantilloDate: Thursday, July 18, 2024Time: 4:05 PM – 4:20 PM EDT Location: Liberty N-P Heartflow invites attendees to two sponsored events, including “Women in CT Happy Hour,” which will take place on July 18 from 6:00 PM – 7:00 PM EDT in the 2nd Floor Lobby, and “The Power of HeartFlow AI in the Management of CAD from Diagnosis to Treatment” symposium, which will take place on July 19 from 11:55 AM – 12:45 PM EDT in the Capitol/Congress Room. About HeartFlow, Inc.HeartFlow is transforming precision coronary care with the only AI-powered non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guideline, HeartFlow continues to advance the diagnosis and management of CAD. HeartFlow’s suite of non-invasive technologies includes its FFRCT Analysis, RoadMap™Analysis, and Plaque Analysis. To date, more than 500 peer-reviewed publications have validated our approach and, more importantly, our technologies have helped clinicians diagnose and manage over 250,000 patients. For more information, visit www.heartflow.com. Media ContactLinly KuSr. Digital Marketing Managermedia@heartflow.com Investor ContactNick Laudico VP of Business Development and Investor Relationsnlaudico@heartflow.com

Continue Reading →

TeleSpecialists Revolutionizes Stroke Care with Launch of Innovative EMS Integration Service

Neuro by Comments are Disabled

EMS Integration to enhance door-to-needle times and elevate patient outcomes
FORT MYERS, Fla., July 16, 2024 /PRNewswire/ — TeleSpecialists, LLC, the nation’s largest inpatient provider of TeleStroke and TeleNeurology services, launches its EMS Integration service as an enhancement to its current neurology services. This new service will allow TeleSpecialists’ board-certified neurologists to expedite stroke treatment and improve patient outcomes.
TeleSpecialists introduces the EMS Integration service for EMS and local hospitals, to enhance patient care in telestroke and teleneurology. This program enables physicians to interact with EMS teams, and hospitals simultaneously during patient transport. Early teleneurology involvement reduces door-to-needle times by connecting a neurologist on-screen during transit to conduct essential tests. With improved efficiency and collaboration, patients can receive a CT scan immediately upon arrival at the hospital. 
“At TeleSpecialists, we are dedicated to pioneering innovations that enhance patient care. Our EMS Integration service represents a major advancement in our ability to improve patient outcomes, particularly in stroke care,” said Nima Mowzoon, MD, MBA, CEO of TeleSpecialists. “By enabling real-time neurology consultations en route to the hospital, we can significantly expedite treatment times and save more lives. This initiative is a testament to our commitment to leveraging technology to deliver the highest quality care to our communities.”
The introduction of the EMS Integration program emphasizes the organization’s commitment to clinical collaboration and continuous improvement in stroke care. This program aims to establish seamless communication between EMS providers and TeleSpecialists to provide timely and effective care for stroke patients in diverse settings. By integrating EMS into its TeleNeurology processes, the company seeks to optimize the delivery of critical interventions and resources, ultimately improving patient outcomes.
The launch of the EMS Integration program at Oak Hill and Bayonet Point Hospital in Hernando County marks a significant milestone in expanding and enhancing TeleSpecialists’ services. With over 10 years of experience and over one million patients seen, this initiative underscores the company’s commitment to delivering improved outcomes to these communities.
About TeleSpecialists, LLCAs the leader in TeleStroke and TeleNeurology and a reliable provider of exceptional TelePsychiatry services in the US, we lead the industry with unmatched quality, scale, and expertise. We seamlessly integrate cutting-edge technology with compassionate care, always striving to preserve and enhance lives through our commitment to excellence.
SOURCE TeleSpecialists

Continue Reading →

Vectorious Medical Technologies Announces First U.S. Patient Implanted with the V-LAP Left Atrial Pressure Sensor

Rhythm by Comments are Disabled

TEL AVIV, Israel, July 16, 2024 /PRNewswire/ — A patient in Cincinnati has become the first in the United States to receive an innovative system that enables remote monitoring of his heart and congestion status, as well as self-adjustment of diuretics.

Continue Reading

First U.S. Patient Implanted with the V-LAP Left Atrial Pressure Sensor by Vectorious Medical Technologies: A New Treatment Paradigm for Heart Failure Patients

Vectorious Medical Technologies Ltd. developed a miniature pressure sensor that is implanted within the heart via standard minimally invasive transvenous catheterization. The sensor measures Left Atrial Pressure (LAP), the earliest and most accurate indicator of fluid overload and congestion status. The system supports a scalable, physician-directed patient self-management approach, allowing heart failure (HF) patients to take an active role in managing their disease. By using the V-LAP system, patients can better understand their disease and adjust diuretics, daily activities, and fluid volume accordingly.

The first V-LAP implantation in the United States was performed by Sitaramesh Emani, MD, Director of Heart Failure Clinical Trials at The Christ Hospital in Cincinnati, Ohio. To date, 56 V-LAP implantations have been performed, resulting in more than 40,000 days of LAP monitoring. This study, together with the ongoing clinical program in Europe and Israel, will further inform an upcoming U.S. pivotal trial.  
“The successful first U.S. V-LAP implantation represents a pivotal moment in heart failure management. By integrating real-time left atrial pressure monitoring into patient care, we are on the cusp of a transformative shift towards more proactive, personalized treatment strategies. This innovative approach aims to improve patient outcomes through a reduction in hospitalizations and enhancement of overall quality of life for heart failure patients, but will do so by empowering patients to actively manage their own care. The data collected from the VECTOR-HF IIb trial will be instrumental in moving our field forward”. Said Dr. Sitaramesh Emani.Initial studies of the V-LAP system, which were recently published in the European Journal of Heart Failure, have shown promising results. During 85% of the overall follow-up duration (26.98 patient-years, 9,593 LAP monitoring days), patient self-management alone, with no physician intervention, was sufficient to keep HF patients without congestion and within safe LAP ranges. This resulted in a significant decrease in the rate of HF-related hospitalizations and a notable improvement in quality of life, based on the 6-minute walk distance and the Kansas City Cardiomyopathy Questionnaire.Eyal Orion, MD, co-founder and CEO of Vectorious, said, “We look forward to expanding our clinical activities in the U.S. and work closely with physicians, nurses, FDA, and our partners towards a pivotal trial. Recent data published in JAMA Cardiology suggests recent plateaus or reversals after long-standing declines in cardiovascular mortality, particularly for HF related mortality in the U.S. between 1999 and 2021. I strongly believe that the technology and Treatment paradigm we develop have the potential to reverse this concerning trend, and our team is fully committed to this mission.”About Vectorious Medical Technologies Ltd.Vectorious is a Tel Aviv-based, privately held company, founded in 2011. The company’s V-LAP System enables heart failure patients to better control their disease by remotely monitoring the heart’s Left Atrial Pressure (LAP) and detecting fluid accumulation in the earliest stages of the disease, prior to physiological symptoms. A patient app further empowers the patient to self-titrate medication in real-time based on data extracted from the heart. For more information, please visit the company website.Contact:Lili Arbely-ElbazVectorious Medical Technologies.+972-(0)525909192[email protected]Photo – https://mma.prnewswire.com/media/2462304/V_LAP_Sensor.jpgSOURCE Vectorious Medical Technologies Ltd.

Continue Reading →

Circle Cardiovascular Imaging Announces Leadership Transition

Uncategorized by Comments are Disabled

CALGARY, AB, July 16, 2024 /PRNewswire/ — Circle Cardiovascular Imaging (“Circle” or the “Company”), the global leader in AI-driven cardiovascular imaging solutions, today announced that Erkan Akyuz has been appointed Chief Executive Officer, effective August 5, 2024. He will succeed Circle co-founder and CEO Greg Ogrodnick, who is stepping down after successfully leading the Company for more than 16 years.
Akyuz brings extensive leadership experience in healthcare and imaging technology, having served as President and CEO at major healthcare and medical systems companies including Rhapsody, Change Healthcare and Toshiba Medical Systems, where, under his leadership, the companies experienced improved profitability, customer retention and growth. Recognized for his ability to transform business models, Akyuz combines his technological background with his strategic prowess to drive operational excellence.
“I have long admired Circle and its role at the forefront of the medical imaging industry, offering best-in-class AI-powered solutions to hospitals, physicians and patients on a global scale,” said Erkan Akyuz. “I am thrilled to be joining this impressive team and look forward to leading Circle as we continue to advance our mission of improving patient outcomes worldwide.”
Akyuz is joining Circle, the leading provider of AI-based cardiac imaging and reporting solutions, during a period of accelerated growth and product innovation. Since Thoma Bravo’s investment in Circle in April 2022, the Company has expanded its global footprint from approximately 50 countries to over 90 countries and has continued to innovate on its cutting-edge AI-driven solutions. Earlier this year, Circle launched its next generation platform, cvi42 6.1, which is centered around growing with the medical field with a focus on accessibility, interoperability and efficiency.
“On behalf of the Thoma Bravo team, I want to thank Greg for his unwavering leadership and commitment to innovation that led Circle to become the category leader that it is today,” said Carl Press, a Partner at Thoma Bravo. “Under Greg’s stewardship, Circle transformed from a university-led research project into a market leading diagnostic platform that has benefitted tens of thousands of cardiology patients globally. We are humbled by the impact that he has made in the world of medical imaging and are truly grateful for our partnership with him. At the same time, we are thrilled to welcome Erkan to Circle and look forward to working closely together as we build on a strong foundation and continue to drive product innovation and growth globally.”
“It has been a privilege to lead the dedicated and passionate team at Circle, and I am proud of what we have achieved together,” said Greg Ogrodnick. “I’m confident that Erkan is the right person to lead Circle in the next phase of its journey, and I look forward to watching the Company’s continued success.”
About Circle Cardiovascular Imaging Inc.     
Circle Cardiovascular Imaging (Circle) is a Canadian-based company that was founded in 2007, established with the aim of developing innovative software solutions to enhance cardiovascular imaging analysis and improve patient care. Circle’s imaging platform provides best-in-class cardiovascular image reading and reporting for cardiac MR, cardiac CT, cardiac interventional planning, and electrophysiology.
At the heart of everything we do is our unrelenting drive to continually offer better solutions for healthcare providers that improve healthcare outcomes. This fuels our creativity, informs our decisions and is the reason we are passionate about our work. Our roots are medical and digital, our passion is contagious, and our people are amongst the best.    
Annually, millions of cardiac exams – in over 1700 hospitals and in more than 90 countries – are estimated to be interpreted using cvi42. For additional information, please visit www.circlecvi.com or contact: [email protected]
SOURCE Circle Cardiovascular Imaging Inc.

Continue Reading →
1 … 234 235 236 237 238 … 1,333